FOLH1 and Familial prostate cancer: However, for response assessment of advanced stage patients [7] or tailoring metastatic castration-resistant prostate cancer (mCRPC) patients with or without tumor PSMA-expression to PSMA-targeted radioligand therapy (RLT) highest sensitivity is not that pivotal and cost-effectiveness and broad availability are more important [8].